Boston's resTORbio Sets Terms for $85M IPO Post author:Sam Post published:January 16, 2018 Post category:BioPharma resTORbio is developing novel therapies to improve immune function in the elderly. Source: BioSpace You Might Also Like American Diabetes Association And Collaborate To Prevent And Delay Type 2 Diabetes September 4, 2017 Illumina Leaves Mission Bay for New Campus in the Peninsula February 15, 2018 Regulus Announces Pricing Of Public Offering Of Common Stock July 19, 2017
